{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:28:41Z","timestamp":1785882521003,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.ijrobp.2005.07.958","type":"journal-article","created":{"date-parts":[[2005,9,29]],"date-time":"2005-09-29T11:16:56Z","timestamp":1127992616000},"page":"408-413","source":"Crossref","is-referenced-by-count":80,"title":["Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group)"],"prefix":"10.1016","volume":"64","author":[{"given":"Peter C.","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-H.","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Olver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant E.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2005.07.958_bib1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib2","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma","volume":"21","author":"Poortmans","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1996.14.2.556","article-title":"Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas","volume":"14","author":"Schultz","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0360-3016(95)00207-F","article-title":"Primary central nervous system non-Hodgkin\u2019s lymphoma","volume":"33","author":"O\u2019Neill","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib5","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9","article-title":"A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma","volume":"89","author":"Mead","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1212\/WNL.58.10.1513","article-title":"A multicenter study of treatment of primary CNS lymphoma","volume":"58","author":"Ferreri","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1200\/JCO.2004.99.259","article-title":"Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas?","volume":"99","author":"Reni","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib8","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2002.20.24.4615","article-title":"Primary central nervous system lymphoma","volume":"20","author":"Fine","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2000.18.3.519","article-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","volume":"18","author":"O\u2019Brien","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1023760824739","article-title":"Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy","volume":"63","author":"Watanabe","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3171\/jns.1994.81.2.0188","article-title":"Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma","volume":"81","author":"Glass","year":"1994","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib12","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.20.1.231","article-title":"Importance of radiotherapy in the outcome of patients with primary CNS lymphoma","volume":"20","author":"Bessell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib14","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/WNL.46.6.1757","article-title":"Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy","volume":"46","author":"Cher","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.46.2.435","article-title":"Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients","volume":"46","author":"Freilich","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib16","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.1998.16.9.3000","article-title":"Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma","volume":"16","author":"Sandor","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1006210703827","article-title":"Intravenous methotrexate as initial treatment for primary central nervous system lymphoma","volume":"43","author":"Guha-Thakurta","year":"1999","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1080\/1042819021000006420","article-title":"Primary central nervous system lymphoma in immunocompetent adults","volume":"43","author":"Depil","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ana.10102","article-title":"German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma","volume":"51","author":"Herrlinger","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib20","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","article-title":"Primary central nervous system lymphoma","volume":"21","author":"Pels","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib21","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1946::AID-CNCR19>3.0.CO;2-T","article-title":"Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma","volume":"82","author":"Cheng","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/028418602317314037","article-title":"Age-adjusted chemotherapy for primary central-nervous system lymphoma","volume":"41","author":"Goldkuhl","year":"2002","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib23","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00006123-200001000-00010","article-title":"Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma","volume":"46","author":"McAllister","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib25","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.01.161","article-title":"Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma","volume":"23","author":"Nguyen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.20.1.197","article-title":"Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma","volume":"20","author":"Shenkier","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1200\/JCO.1997.15.6.2275","article-title":"Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin\u2019s disease","volume":"15","author":"Loeffler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.07.958_bib28","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","article-title":"Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years","volume":"21","author":"Hoang-Xuan","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301605021450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301605021450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T02:27:35Z","timestamp":1548124055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301605021450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0360301605021450"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2005.07.958","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}